If there is an offer for ACTIPATCH, it will most definitely be contingent on FDA full clearance. Don't know if it is sitting on AW desk or was whispered in his ear, but I think we all know that a sale price will be most beneficial to company if the "BACK" is cleared, leading to 'full clearance'. If there is no offer as of yet, my opinion is that FDA FULL CLEARANCE would be the news that might/could entice one to make an offer. Who knows who is watching this company with what is going on now with FDA trials and clearances. If they ARE watching, then they know of the immense potential these products can achieve in a most lucrative ($$) market. Maybe this is what's holding back the Smart Sole / Dr. Scholls licensing deal. Could there be a perspective buyer for all (BAYER)? Personally, if/when we do see a Dr. Scholls licensing deal, I would like to see the Actipatch go the same route. Like the idea of 'licensing' product to major player with all marketing lines already established. For a small upstart like Bioelectronics, that is a major task. Although with the distributor deals we appear to be negotiating now, that task would become so much easier. Either way we go, I see a positive result to the stock holders. And by AW's statement of the only type of offer he would consider for selling the company, I think he sees the same.
All just food for thought.
AI
Market Data 
Markets 
